266 related articles for article (PubMed ID: 37042149)
1. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
2. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
PeerJ; 2024; 12():e16923. PubMed ID: 38374950
[TBL] [Abstract][Full Text] [Related]
3. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
[TBL] [Abstract][Full Text] [Related]
4. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
[TBL] [Abstract][Full Text] [Related]
5. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract][Full Text] [Related]
6. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
[TBL] [Abstract][Full Text] [Related]
7. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N
Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572
[TBL] [Abstract][Full Text] [Related]
9. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract][Full Text] [Related]
10. A Subset of Thoracic SMARCA4-Deficient Undifferentiated Tumors Express GATA3.
Coconubo DM; Wangsiricharoen S; Pettus JR; Linos K; Pinto A; Wang WL; Kerr DA; Cloutier JM
Int J Surg Pathol; 2024 Jun; 32(4):684-691. PubMed ID: 37461275
[TBL] [Abstract][Full Text] [Related]
11. Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature.
Mundada M; Mannan KA; Vasu D; Ahmed F; K S
Turk Patoloji Derg; 2024; 40(2):128-133. PubMed ID: 38265099
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
[TBL] [Abstract][Full Text] [Related]
13. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
14. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
Chatzopoulos K; Boland JM
Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
[TBL] [Abstract][Full Text] [Related]
15. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
[TBL] [Abstract][Full Text] [Related]
16. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
Rekhtman N; Montecalvo J; Chang JC; Alex D; Ptashkin RN; Ai N; Sauter JL; Kezlarian B; Jungbluth A; Desmeules P; Beras A; Bishop JA; Plodkowski AJ; Gounder MM; Schoenfeld AJ; Namakydoust A; Li BT; Rudin CM; Riely GJ; Jones DR; Ladanyi M; Travis WD
J Thorac Oncol; 2020 Feb; 15(2):231-247. PubMed ID: 31751681
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report.
Yang P; Xiong F; Lin Y; Liang P; Tang C
Transl Cancer Res; 2023 Apr; 12(4):1041-1048. PubMed ID: 37180644
[TBL] [Abstract][Full Text] [Related]
18. Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure.
Shi L; Lin L; Ding Y; Zeng Y; Chen X
Front Oncol; 2022; 12():1020875. PubMed ID: 36452500
[TBL] [Abstract][Full Text] [Related]
19. Cytopathological Features of
Takeda M; Tani Y; Saijo N; Shimizu S; Taniguchi Y; Otsuka K; Nakao K; Tamiya A; Okishio K; Atagi S; Ohbayashi C; Kasai T
Int J Surg Pathol; 2020 Feb; 28(1):109-114. PubMed ID: 31448657
[No Abstract] [Full Text] [Related]
20. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
